Barclays Upgrades Stryker (NYSE:SYK) to “Strong-Buy”

Posted by Brenda Bartman on Oct 9th, 2026

Stryker (NYSE:SYK – Get Free Report) was upgraded by investment analysts at Barclays to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

Other analysts have also issued reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Canaccord Genuity Group lowered their price objective on shares of Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. Finally, Royal Bank Of Canada reduced their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $370.68.

Check Out Our Latest Report on Stryker

Stryker Stock Performance

Shares of SYK stock opened at $276.56 on Wednesday. The firm has a 50-day moving average of $305.39 and a 200-day moving average of $314.60. The company has a market cap of $106.08 billion, a P/E ratio of 28.66, a P/E/G ratio of 1.74 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker has a one year low of $267.00 and a one year high of $392.55.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period last year, the firm earned $3.13 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker will post 14.97 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sankala Group LLC purchased a new position in Stryker in the fourth quarter worth $26,000. Gables Capital Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $25,000. Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC raised its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. Finally, Highland Investment Advisors LLC bought a new stake in Stryker in the 2nd quarter worth approximately $25,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Barclays upgraded Stryker to “strong buy,” signaling greater confidence in the medical-device maker’s outlook and suggesting the recent selloff may have created an attractive entry point. Stryker Upgraded to Strong-Buy at Barclays
Positive Sentiment: Analysts described incoming CEO Spencer Stiles’ transition as low-risk, reducing concerns about leadership continuity. The appointment supported the shares, although Truist lowered its price target to $310. Stryker Stock in Focus as Truist Assesses CEO Transition
Positive Sentiment: A separate analysis argued that Stryker could be undervalued after its 26% slide, potentially drawing investors seeking exposure to a leading medical-technology company at a lower valuation. Stryker Stock Could Be Cheap After Its 26% Slide
Neutral Sentiment: Reports highlighted Stryker’s market capitalization and current trading level but did not identify a new operational catalyst. Stryker Stock and Market Capitalization
Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Stryker investors. Although the announcement does not establish wrongdoing, it adds litigation-related uncertainty and may weigh on sentiment. Pomerantz Investor Alert Regarding Stryker

Stryker Company Profile

(Get Free Report)

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.